Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b plus TAF continuous versus pulse therapy in HBeAg-negative chronic hepatitis B
ChiCTR2100045165Phase 4Recruiting
- Sponsor
- Jinan Infectious Disease Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Jinan Infectious Disease Hospital. Primary endpoint: HBsAg clearance rate at the end of treatment. Started Apr 2021; status: recruiting.
02
Drugs
peginterferon alfa-2btenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100045165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045165.